Membrane designs and composition for hemodialysis, hemofiltration and hemodialfiltration: Past, present and future

Minerva Urologica e Nefrologica

Volumn 62, Issue 1, 2010, Pages 29-40

  Davenport, A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Dialysis; Hemodiafiltration; Hemofiltration; Membranes

Indexed keywords

BRADYKININ; CELLULOSE; DIETHYLAMINOETHYL CELLULOSE; MACROGOL; POLY(METHYL METHACRYLATE); POLYACRYLONITRILE; POLYAMIDE; POLYCARBONATE; POLYSULFONE; PYROXYLIN;

ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; CHRONIC KIDNEY DISEASE; DIALYSIS MEMBRANE; HEMODIAFILTRATION; HEMODIALYSIS; HEMOFILTRATION; HUMAN; HYPOTENSION; INSTRUMENT STERILIZATION; MEMBRANE PERMEABILITY; PROTEIN BINDING; REVIEW; SOLUTE; SURFACE PROPERTY; UREMIA;

CELLULOSE; HEALTH CARE COSTS; HEMODIAFILTRATION; HEMODIALYSIS SOLUTIONS; HEMOFILTRATION; HUMANS; KIDNEY FAILURE, ACUTE; KIDNEY FAILURE, CHRONIC; MEMBRANES, ARTIFICIAL; METABOLIC CLEARANCE RATE; POLYMERS; RENAL DIALYSIS; WATER-ELECTROLYTE BALANCE;

EID: 77953526220     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Twardowski ZJ. History of hemodialyzers' design. Hemodial Int 2008;12:173-210.
2. Kil F. Development of parallel flow artificial kidney. Acta Chir Scand 1960;(Suppl 253):142-50.
3. von Garrelts B. A blood dialyzer for use in vivo. Acta Med Scand. 1956; CLV (fasc II): 87-94
4. Stewart RD, Lipps BJ, Baretta ED, Piering WR, Roath DA, Sargent JA. Short term hemodialysis with the capillary kidney. Trans Am Soc Artif Organs. 1968; 14: 121-125
5. Davenport A, Will EJ, Davison AM. The effect of the direction of dialysate flow on the efficiency of CAVHD. Blood Purif 1990;8:329-36.
6. Leypoldt JK, Kamerath CD, Gilson JF, Friederichs G. Dialyzer clearances and mass transfer-area coefficients for small solutes at low dialysate flow rates. ASAIO J 2006;52:404-9.
7. Leypoldt JK, Cheung AK, Chirananthavat T, Gilson JF, Kamerath CD, Deeter RB. Hollow fiber shape alters solute clearances in high flux hemodialyzers. ASAIO J 2003;49:81-7.
8. Mulzer SR, Brash JL. Identification of plasma proteins adsorbed to hemodialyzers during clinical use. J Biomed Mater Res 1989;23:1483-504.
9. Davenport A. Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient hemodialysis treatments. Nephrology (Carlton) 2009;14:455-61.
10. Lavaud S, Paris B, Maheut H, Randoux C, Renaux JL, Rieu P et al. Assessment of the heparin-binding AN69 ST hemodialysis membrane: II. Clinical studies without heparin administration. ASAIO J 2005;51:348-51.
11. Betjes MG, Hoekstra FM, Klepper M, Postma SM, Vaessen LM. Vitamin E-coated dialyzer membranes down regulate expression of monocyte adhesion and co-stimulatory molecules. Blood Purif 2004;22:510-7.
12. Ferraro B, Galli F, Frei B, Kingdon E, Canestrari F, Rice-Evans C et al. Peroxynitrite-induced oxidation of plasma lipids is enhanced in stable hemodialysis patients. Kidney Int 2003;63:2207-13.
13. Craddock PR, Fehr J, Brigham KL, Kronenberg RS, Jacob HS. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med 1977;296:769-74.
14. Kaplow LS, Goffinet JA. Profound neutropenia during the early phase of hemodialysis. JAMA 1968;203:1135-7.
15. Davenport A, Davison AM, Will EJ. Does membrane biocompatibility effect cardiovascular stability in critically ill patients treated by machine hemofiltration? Kid Int 1993;43(Suppl 41):S230-4.
16. Sperschneider H, Deppisch R, Beck W, Wolf H, Stein G. Impact of membrane choice and blood flow pattern on coagulation and heparin requirement potential consequences on lipid concentrations. Nephrol Dial Transplant 1997;12:2638-46.
17. Schiffl H, Lang SM, König A, Strasser T, Haider MC, Held E. Biocompatible membranes in acute renal failure: prospective case-controlled study. Lancet 1994;27:570-2.
18. Hakim RM, Wingard RL, Parker RA. Effect of the dialysis membrane in the treatment of patients with acute renal failure. N Engl J Med 1994;331:1338-42.
19. Parker TF 3rd, Wingard RL, Husni L, Ikizler TA, Parker RA, Hakim RM. Effect of the membrane biocompatibility on nutritional parameters in chronic hemodialysis patients. Kidney Int 1996;49:551-6.
20. Tayeb JS, Provenzano R, El-Ghoroury M, Bellovich K, Khairullah Q, Pieper D et al. Effect of biocompatibility of hemodialysis membranes on serum albumin levels. Am J Kidney Dis 2000;35:606-10.
21. Jörres A, Gahl GM, Dobis C, Polenakovic MH, Cakalaroski K, Rutkowski B et al. Hemodialysis-membrane biocompatibility and mortality of patients with dialysis-dependent acute renal failure: a prospective randomised multicentre trial. International Multicentre Study Group. Lancet 1999;354:1337-41.
22. Gastaldello K, Melot C, Kahn RJ, Vanherweghem JL, Vincent JL, Tielemans C. Comparison of cellulose diacetate and polysulfone membranes in the outcome of acute renal failure: a prospective randomised study. Nephrol Dial Transplant 2000;15:224-30.
23. Alonso A, Lau J, Jaber BL Biocompatible hemodialysis membranes for acute renal failure. Cochrane Database Syst Rev 2008;1:CD005283.
24. Davenport A. Can dialyzer membrane selection affect outcomes in patients with acute kidney injury requiring dialysis? Hemodial Int 2009;13(s1):S13-S7.
25. Krane V, Krieter DH, Olschewski M, März W, Mann JF, Ritz E et al. Dialyzer membrane characteristics and outcome of patients with type 2 diabetes on maintenance hemodialysis. Am J Kidney Dis 2007;49:267-75.
26. Götz AK, Böger CA, Popal M, Banas B, Krämer BK. Effect of membrane flux and dialyzer biocompatibility on survival in end-stage diabetic nephropathy. Nephron Clin Pract 2008;109:c154-60.
27. Davenport A. Intradialytic complications during hemodialysis. Hemodial Int 2006;10:162-7.
28. Davenport A. The role of dialyzer membrane flux in bio-incompatibility. Hemodial Int 2008;12(Suppl 2): S29-S33.
29. Eknoyan G, Beck GJ, Cheung AK, Daugirdas JT, Greene T, Kusek JW et al. Hemodialysis (HEMO) Study Group. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002;347:2010-9.
30. Koda Y, Nishi S, Miyazaki S, Haginoshita S, Sakurabayashi T, Suzuki M et al. Switch from conventional to high-flux membrane reduces the risk of carpal tunnel syndrome and mortality of hemodialysis patients. Kidney Int 1997;52:1096-101.
31. Cheung AK, Rocco MV, Yan G, Leypoldt JK, Levin NW, Greene T et al. Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 2006;17:546-55.
32. Locatelli F, Martin-Malo A, Hannedouche T, Loureiro A, Papadimitriou M, Wizemann V et al. Membrane Permeability Outcome (MPO) Study Group. Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 2009;20:645-54.
33. Davenport A, Farrington K. Dialysis dose and survival in AKI: lessons from chronic dialysis? Lancet 2010 [In press].
34. Lonnemann G, Sereni L, Lemke HD, Tetta C. Pyrogen retention by highly permeable synthetic membranes during in vitro dialysis. Artif Organs 2001;25:951-60.
35. Schindler R, Beck W, Deppisch R, Aussieker M, Wilde A, Göhl H et al. Short bacterial DNA fragments: detection in dialysate and induction of cytokines. J Am Soc Nephrol 2004;15:3207-14.
36. Pedrini LA, Zerbi S. Mixed-dilution hemodiafiltration. Contrib Nephrol 2007;158:123-30.
37. Davenport A. Low molecular weight heparin for routine hemodialysis. Hemodial Int 2008;12(Suppl 2):S34-S7.
38. Spalding EM, Chandna SM, Davenport A, Farrington K. Kt/V underestimates the hemodialysis dose in women and small men. Kidney Int 2008;74:348-55.
39. Haase M, Bellomo R, Morgera S, Baldwin I, Boyce N. High cut-off point membranes in septic acute renal failure: a systematic review. Int J Artif Organs 2007;30:1031-41.
40. Hutchison CA, Harding S, Mead G, Goehl H, Storr M, Bradwell A et al. Serum free-light chain removal by high cutoff hemodialysis: optimizing removal and supportive care. Artif Organs 2008;32:910-7.
41. Rimmele T, Assadi A, Cattenoz M, Desebbe O, Lambert C, Boselli E et al. High volume hemofiltration with a new hemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009;24:421-7.
42. Ronco C, Brendolan A, Lonnemann G, Bellomo R, Piccinni P, Digito A et al. A pilot study of coupled plasma filtration with adsorption in septic shock. Crit Care Med 2002;30:1250-5.
43. Davenport A. Pyrexia of unknown origin in a hemodialysis patient. NDT Plus 2008;1:109-11.
44. Ebo DG, Bosmans JL, Couttenye MM, Stevens WJ. Hemodialysis-associated anaphylactic and anaphylactoid reactions. Allergy 2006;61:211-20.
45. Canaud B, Aljama P, Tielemans C, Gasparovic V, Gutierrez A, Locatelli F. Pathochemical toxicity of perfluorocarbon-5070, a liquid test performance fluid previously used in dialyzer manufacturing, confirmed in animal experiment. J Am Soc Nephrol 2005;16:1819-23.
46. Coppo R, Amore A, Cirina P, Salfur B, Giachino F, Commone L et al. Bradykinin and nitric oxide generation by dialysis membranes can be blunted by alkaline rinsing solutions. Kidney Int 2000;58:881-8.
47. Stoves J, Goode NP, Visvanathan R, Jones CH, Shires M, Will EJ et al. The bradykinin response and early hypotension at the introduction of continuous renal replacement therapy in the intensive care unit. Artif Organs 2000;25:1009-21.
48. Kishimoto TK, Viswanathan K, Ganguly T, Elankumaran S, Smith S, Pelzer K et al. Contaminated heparin associated with adverse clinical events and activation of the contact system. N Engl J Med 2008;358:2457-67.
49. Leypoldt JK, Cheung AK. Increases in mass transfer-area coefficients and urea Kt/V with increasing dialysate flow rate are greater for high-flux dialyzers. Am J Kidney Dis 2001;38:575-9.